Hodges Capital Management’s Emergent Biosolutions EBS Stock Holding History

Hodges Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-6,524	Closed	-$585K	–	224
2020 Q4	$585K	Sell	6,524 -9,323	-59%	-$856K	0.09%	147
2020 Q3	$1.64M	Sell	15,847 -50,815	-76%	-$5.48M	0.32%	95
2020 Q2	$5.27M	Buy	66,662 +30,089	+82%	+$2.24M	1.08%	26
2020 Q1	$2.12M	Buy	+36,573	New	+$2.11M	0.54%	60
2018 Q2	–	Sell	-30,000	Closed	-$1.58M	–	254
2018 Q1	$1.58M	Sell	30,000 -25,000	-45%	-$1.25M	0.12%	131
2017 Q4	$2.56M	Sell	55,000 -25,000	-31%	-$1.05M	0.19%	105
2017 Q3	$3.24M	Hold	80,000	–	–	0.22%	98
2017 Q2	$2.71M	Buy	80,000 +25,000	+45%	+$772K	0.16%	112
2017 Q1	$1.6M	Buy	55,000 +22,000	+67%	+$670K	0.08%	142
2016 Q4	$1.08M	Buy	+33,000	New	+$989K	0.05%	166

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hodges Capital Management's EBS Position: Q1 2021 in Review

Hodges Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 6,524 shares — an estimated $585K sold.

Hodges Capital Management first reported a position in EBS in Q4 2016 and held it in 10 quarters. The position peaked at $5.27M in Q2 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

Hodges Capital Management reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
Hodges Capital Management sold 6,524 Emergent Biosolutions shares in Q1 2021, an estimated $585K.
Hodges Capital Management first reported a position in Emergent Biosolutions in Q4 2016 and held it in 10 quarters.
Hodges Capital Management's Emergent Biosolutions position peaked at $5.27M in Q2 2020.
340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on Hodges Capital Management's 13F filing for Q1 2021, filed 7 Apr 2021.